[HTML][HTML] 24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation
C Zhu, N Boucheron, AC Müller, P Májek, T Claudel… - Journal of …, 2021 - Elsevier
Abstract Background & Aims 24-NorUrsodeoxycholic acid (NorUDCA) is a novel therapeutic
bile acid for immune-mediated cholestatic liver diseases, such as primary sclerosing
cholangitis (PSC) where dysregulated T-cells including CD8+ T-cells contribute to
hepatobiliary immunopathology. We hypothesized that NorUDCA may directly modulate
CD8+ T-cell function thus contributing to its therapeutic efficacy. Methods NorUDCA's
immunomodulatory effects were first studied in Mdr2-/-mice as cholestatic model of PSC. To …
bile acid for immune-mediated cholestatic liver diseases, such as primary sclerosing
cholangitis (PSC) where dysregulated T-cells including CD8+ T-cells contribute to
hepatobiliary immunopathology. We hypothesized that NorUDCA may directly modulate
CD8+ T-cell function thus contributing to its therapeutic efficacy. Methods NorUDCA's
immunomodulatory effects were first studied in Mdr2-/-mice as cholestatic model of PSC. To …
